Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Grows By 29.2%

Xenetic Biosciences Inc (NASDAQ:XBIO) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 8,400 shares, an increase of 29.2% from the February 13th total of 6,500 shares. Based on an average daily volume of 8,800 shares, the short-interest ratio is presently 1.0 days. Approximately 0.7% of the shares of the company are sold short.

Xenetic Biosciences Trading Up 3.2 %

NASDAQ:XBIO opened at $3.50 on Monday. The company has a market capitalization of $5.40 million, a P/E ratio of -1.32 and a beta of 2.17. The firm has a 50-day moving average price of $4.04 and a two-hundred day moving average price of $4.01. Xenetic Biosciences has a twelve month low of $2.78 and a twelve month high of $5.20.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Xenetic Biosciences in a research note on Thursday, December 5th.

Institutional Trading of Xenetic Biosciences

A hedge fund recently bought a new position in Xenetic Biosciences stock. LGT Group Foundation bought a new stake in shares of Xenetic Biosciences Inc (NASDAQ:XBIO) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned approximately 0.71% of Xenetic Biosciences at the end of the most recent quarter. 15.12% of the stock is owned by hedge funds and other institutional investors.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.